Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was anticipating.

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook observed through 1H24. Read more here.

Eli Lilly’s blockbuster weight loss and diabetes drugs missed analysts’ expectations by 18% in the third quarter, which were negatively impacted by inventory stocking in the wholesaler channel. The company’s shares fell more than 13% in trading on Wednesday morning.

Eli Lilly and Company (LLY) stock is down in Wednesday's premarket trading after the pharmaceutical company reported third quarter results that missed revenue expectations. The disappointing performance was driven by lower-than-anticipated sales of the company's weight loss drug,

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a comparison with an alternate stock I prefer.

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss medicine Zepbound will be virtually bottomless. After the company reported disappointing third-quarter results Wednesday morning,